Phenomenex to Distribute Beckman Coulter’s IgY Proteome Enrichment Chemistry for Biomarker Discovery
News Jun 08, 2007
The agreement grants Phenomenex exclusive distribution rights in the United States, Canada and countries in the European Union. Based on avian-generated antibodies, ProteomeLab IgY-12 liquid chromatography and spin columns offer cleaner capture and broader antigen-binding host range than other protein depletion/ partitioning methods because of the evolutionary distance between chickens and mammals.
"Protein partitioning is a critical part of any biomarker discovery program and we view the ProteomeLab IgY products as the best available," commented Michael McGinley, Phenomenex Biochromatography Product Manager. "These columns fit well with our portfolio of complete proteomics solutions for the separation of proteins and peptides.”
Highly abundant proteins can significantly mask potential markers and impede the discovery of biomarker targets. ProteomeLab IgY-12 columns selectively partition 12 highly abundant proteins, up to 96% of the protein mass, from human/primate serum, plasma or cerebrospinal fluid.
IgY-R7 columns partition 7 highly abundant rodent proteins, while single-component kits specifically capture a choice of seven key highly abundant plasma proteins, enabling a more targeted approach for specific protein partitioning. IgY delivers an enriched proteome that includes medium- and low-abundance proteins that are of interest to biomarker research.
“The ProteomeLab IgY product line has experienced double digit growth since its introduction in 2005 and we have been looking for ways to make it available to more researchers,” commented Jerry Feitelson, business development manager for Beckman Coulter. “We see Phenomenex as a valuable strategic partner to expand the leadership of this product line in biomarker discovery sample preparation.”
"Being specifically focused on consumable separation devices, Phenomenex is ideally suited to best serve the customer's needs," commented Catherine Cordova, Phenomenex Biochromatography brand manager. "Our international network of technical consultants can provide instant support for this product." The IgY products will continue to be sold under Beckman Coulter's ProteomeLab brand.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.